Abstracts tagged "Infection"

Abstract Number: 1228 • 2018 ACR/ARHP Annual Meeting
Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study
Géraldine Bart¹, Guillaume Coiffier², Oriane Merot³, Emmanuel Hoppe⁴, Marion Couderc⁵, Denis Mulleman⁶, Gregoire Cormier⁷, Jean Marc Ziza⁸ and Benoit Le Goff¹, ¹Rheumatology, Nantes University Hospital, Nantes, France, ²Rheumatology, Rennes University Hospital, Rennes, France, ³rheumatology unit, Saint Nazaire Hospital, Saint Nazaire, France, ⁴Angers University Hospital, Angers, France, ⁵Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁶Université François-Rabelais de Tours, CNRS 7292, Tours, France, ⁷Service de Rhumatologie, CHD de la Roche-Sur-Yon, La Roche-Sur-Yon, France, ⁸Medecine Interne-Rhumatologie, Groupe hospitalier Diaconesses-Croix-Saint-Simon, Paris, France
Background/Purpose: In a previous work, we showed that neurological complication can occur in up to 40% of patients with vertebral osteomyelitis (VO). Bed rest and…
Abstract Number: 2717 • 2018 ACR/ARHP Annual Meeting
Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized–Controlled Trials
Lafarge Antoine¹, Christian Pagnoux², Xavier Puéchal³, Maxime Samson⁴, Mohamed Hamidou⁵, Alexandre Karras⁶, Thomas Quémeneur⁷, Matthieu Groh⁸, Luc Mouthon³, Loïc Guillevin³ and Benjamin Terrier⁹, ¹Medecine Interne, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ³Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, François-Mitterrand Teaching Hospital, University of Bourgogne-Franche-Comté, Dijon, France, ⁵Department of Internal Medicine, CHU de Nantes, France, Nantes, France, ⁶Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, Paris, France, ⁷Department of Internal Medicine, CH of Valenciennes, France, Valenciennes, France, ⁸Internal Medicine, Foch, Suresnes, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Although overall survival of patients with systemic necrotizing vasculitides (SNVs) has improved markedly over the last 20 years, infectious complications remain a major cause…
Abstract Number: 1229 • 2018 ACR/ARHP Annual Meeting
Diagnosing Prosthetic Joint Infections in Patients with Inflammatory Arthritis
Serene Z. Mirza¹, Shawn Richardson², Cynthia Kahlenberg², Jason Blevins², Michelle Demetres³, Lily Martin³, Jackie Szymonifka², Peter K. Sculco⁴, Mark P. Figgie⁵ and Susan M. Goodman², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Weill Cornell Medicine, New York, NY, ⁴Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Surgery, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with inflammatory arthritis (IA) are at increased risk of prosthetic joint infections, yet differentiating between septic and aseptic failure is a challenge in…
Abstract Number: 2832 • 2018 ACR/ARHP Annual Meeting
Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
Sheng-Xiao Zhang¹, Xiao-Yan Wu², Jing Luo³, Guang-Ying Liu², Chong Gao⁴, Cai-Hong Wang⁵ and Xiao-Feng Li⁵, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁵The Second Hospital of Shanxi Medical Univerity, Taiyuan, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by disturbed cellular and humoral immune responses. Dysregulations of intrinsic or adaptive immune system…
Abstract Number: 1231 • 2018 ACR/ARHP Annual Meeting
Pyogenic Vertebral Osteomyelitis: Outcome Variables Analysis in a 116 Patients Cohort at a Tertiary Hospital during the Last 8 YEARS
Jorge Juan Fragio Gil¹, Roxana Gonzalez Mazario¹, Francisco Miguel Ortiz-Sanjuán¹, Jose Ivorra Cortes¹, Elena Grau Garcia¹, Karla Arevalo¹, Isabel Martinez Cordellat¹, Inmaculada Chalmeta Verdejo¹, Jose Eloy Oller Rodriguez¹, Luis Gonzalez Puig¹, Marta De la Rubia Navarro¹, Rosa Negueroles Albuixech¹, Cristina Alcañiz Escandell², Elvira Vicens Bernabeu¹, Eva Calabuig³, Maria Tasias Pitarch³, Miguel Salavert Lleti³ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²IIS La Fe, Valencia, Spain, ³Infectious Diseases Unit. Hospital Universitario y Politecnico La Fe, Valencia, Spain
Background/Purpose: Vertebral Osteomyelitis is an infectious disease of the vertebral body which could involve the intervertebral space (spondylodiscitis). Early diagnosis and treatment are essential in…
Abstract Number: 2858 • 2018 ACR/ARHP Annual Meeting
Gaps in Patient Safety Performance before Treatment with Biologic Disease-Modifying Antirheumatic Drugs or Tofacitinib in a Large Academic Healthcare System
Sarah L. Patterson¹, Michael Evans², Ishita Aggarwal³, Zara Izadi⁴, Milena Gianfrancesco⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California - San Francisco, San Francisco, CA, ³Medicine, Santa Clara Valley Medical Center, San Jose, CA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶San Francisco VA Medical Center, San Francisco, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Treatment with biologic disease-modifying antirheumatic drugs (DMARDs) and tofacitinib confer increased risk of life-threatening infections, including reactivation of latent tuberculosis infection (LTBI), hepatitis B…
Abstract Number: 218 • 2018 ACR/ARHP Annual Meeting
Risk of Serious Infection Associated with TNF Inhibitor Versus Triple Therapy in Rheumatoid Arthritis Patients
Yinzhu Jin¹, Eun Ha Kang², Rishi J. Desai³, Angela Tong¹ and Seoyoung C. Kim^4,5, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ³Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Treatment with tumor necrosis factor inhibitor (TNFi) with methotrexate or triple therapy (MTX, sulfasalazine, and sulfasalazine) is considered in patients with rheumatoid arthritis (RA)…
Abstract Number: 1233 • 2018 ACR/ARHP Annual Meeting
Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study
Raul Castellanos-Moreira Sr.¹, Sebastian C Rodriguez-Garcia¹, M. Victoria Hernández², Virginia Ruiz-Esquide³, Oscar Camacho Sr.¹, Andrea Cuervo¹, Julio Ramírez³, Juan Cañete¹, Jose Gomez Puerta¹ and Raimon Sanmarti¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment rheumatoid arthritis (RA) patients who failed to respond to tumor necrosis factor inhibitors.…
Abstract Number: 227 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Treated with Abatacept, Rituximab and Tocilizumab in Denmark and Sweden: Risk of Serious Infections
Kathrine Lederballe Grøn¹, Elizabeth V. Arkema², Bente Glintborg¹, Frank Mehnert³, Mikkel Østergaard⁴, Lene Dreyer⁵, Mette Nørgaard³, Niels Steen Krogh⁶, Johan Askling⁷ and Merete Lund Hetland⁸, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Aarhus University Hospital, Clinical Epidemiological Department, Aarhus, Denmark, ⁴The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁵Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ⁶ZiteLab ApS, Copenhagen, Denmark, ⁷Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸DANBIO Registry, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark
Background/Purpose: Safety concerns have been raised regarding the risk of serious infections (SI) with the different available biologic disease-modifying anti-rheumatic drugs (bDMARDs). Little is known…
Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
Hung Trinh and Darren Tabechian, Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…
Abstract Number: 237 • 2018 ACR/ARHP Annual Meeting
The Risk of Serious and Opportunistic Infections in Rheumatologic Patients on Interleukin Inhibitors: A Systematic Review and Meta-Analysis
Adam Berlinberg¹, Jawad Bilal², Abdullah Alhifany³, Warda Faridi⁴ and C. Kent Kwoh⁵, ¹Department of Internal Medicine, University of Arizona, Tucson, AZ, ²Internal Medicine, University of Arizona, Tucson, AZ, ³Department of Pharmacy, University of Arizona, Tucson, AZ, ⁴Department of Hematology/Oncology, University of Arizona, Tucson, AZ, ⁵Medicine, Division of Rheumatology, University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ
Background/Purpose: Interleukin (IL) inhibitors are increasingly being used for rheumatologic diseases. There are many controlled clinical trials assessing the efficacy of IL inhibitors, but there…
Abstract Number: 1480 • 2018 ACR/ARHP Annual Meeting
Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database
Eishi Uechi^1,2 and Kiyohide Fushimi², ¹Division of Rheumatology, Tomishiro Central Hospital, Okinawa, Japan, ²Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: Pneumonia is the leading cause of mortality in RA patients. No research has been conducted on the prognosis of pneumonia in RA patients. This…
Abstract Number: 343 • 2018 ACR/ARHP Annual Meeting
Low Rates of Immunizations in Cohort of Immunocompromised Patients in an Academic Rheumatology Practice
Dmitriy Cherny¹, Najia Shakoor², Todd Beck³ and Sonali Khandelwal⁴, ¹Internal Medicine, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Bioinformatics, Rush University Medical Center, Chicago, IL, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatologic disorders often require immunosuppression (e.g. DMARDs, biologics, or high doses of prednisone). These patients are at increased risk for infections. While…
Abstract Number: 1516 • 2018 ACR/ARHP Annual Meeting
Infection Events in Japanese Patients with Rheumatoid Arthritis Treated with Tofacitinib: Interim All-Case Post-Marketing Surveillance
Naoto Tamura¹, Masataka Kuwana², Tatsuya Atsumi³, Syuji Takei⁴, Masayoshi Harigai⁵, Takao Fujii⁶, Hiroaki Matsuno⁷, Tsuneyo Mimori⁸, Shigeki Momohara⁹, Kazuhiko Yamamoto¹⁰, Yoshinari Takasaki¹¹, Kazuto Nomura¹², Yutaka Endo¹², Tomohiro Hirose¹², Yosuke Morishima¹², Naonobu Sugiyama¹², Noritoshi Yoshii¹² and Michiaki Takagi¹³, ¹Juntendo University, Tokyo, Japan, ²Nippon Medical School, Tokyo, Japan, ³Hokkaido University, Sapporo, Japan, ⁴Medical Center for Children, Kagoshima, Japan, ⁵Tokyo Women’s Medical University, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ⁸Kyoto University, Kyoto, Japan, ⁹Hakkeikai Inc Medical Institution, Shizuoka, Japan, ¹⁰The University of Tokyo, Tokyo, Japan, ¹¹Juntendo Koshigaya Hospital, Juntendo University Faculty of Medicine, Saitama, Japan, ¹²Pfizer Japan Inc, Tokyo, Japan, ¹³Yamagata University Faculty of Medicine, Yamagata, Japan
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Previously, the efficacy and safety of tofacitinib were demonstrated in patients (pts)…
Abstract Number: 520 • 2018 ACR/ARHP Annual Meeting
Factors Associated with the Developement of Severe Respiratory Infections in Patients with Rheumatoid Arthritis Included in a Vaccination Program
Lucia C. Domínguez-Casas¹, Paz Rodríguez-Cundín², Vanesa Calvo-Río³, Nuria Vegas-Revenga³, Virginia Portilla⁴, F. Antolin², M. Rebollo-Rodrigo², Alfonso Corrales¹, Diana Prieto Peña³, Monica Calderón Goercke³, Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Preventive Medicine, Preventive Medicine. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain., Santander, Spain, ³Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Rheumatoid arthritis(RA) patients are at increased risk of infections particularly respiratory infections. These may be augmented due to RA itself and to immunosuppressive durgs,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].